Home > Formulary : Adult > Recent Decisions > 2018 >
Decisions 27th November 2018
At the meeting on the 27th November the following decisions were agreed:
New Drug Requests
Approved
Melatonin (amber 3 months)
- Approved for adults with Learning Disabilities with co-morbid mental illness or with sleep disturbances pending an amended SCP
Cacicol®
- Approved for the management of corneal wound healing on the eye
Further work needed
Glycopyrronium
- The group agreed that further work was needed before it could be added onto the Formulary for drooling in Parkinson's disease patient's
Botulinum toxin
- The group agreed that further work was needed before it could be added onto the Formulary for drooling in Parkinson's disease and Motor Neurone Disease
Melatonin
- The group felt there were questions that needed answering before a decision could be made for the use of melatonin for REM Sleep Behaviour Disorder. Unfortunately the applicant was unable to attend. The application will be discussed in April.
Not approved
Melatonin
- Not approved for Delayed Sleep-Wake Phase Disorder
Adex gel
- Not approved for vascular eczema and psoriasis
Shared Care Protocols/TLS Status
- Appeal for change of TLS from amber to green for Dymista® approved.